Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination therapy involving ultrasound-guided stapler-assisted procedure (USG-STAP) with the co-administration of bupivacaine and dexmedetomidine. - **USG-STAP** refers to an interventional technique performed under ultrasound guidance, though the specific "STAP" acronym is not standard in medical literature and may refer to a particular surgical or procedural approach using a stapler device under sonographic visualization[4]. - **Bupivacaine** is a long-acting local anesthetic that blocks sodium channels, inhibiting nerve impulse transmission and providing regional anesthesia or analgesia. - **Dexmedetomidine** is an alpha-2 adrenergic receptor agonist used as an adjuvant to prolong sensory and motor block duration when combined with local anesthetics like bupivacaine[6][8][10]. It provides sedative, anxiolytic, and analgesic effects without significant respiratory depression. The combination of these agents in procedures such as spinal or regional anesthesia has been shown to enhance postoperative analgesia by prolonging sensory block duration and reducing opioid requirements[6][8][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on USG-STAP + bupivacaine + dexmedetomidine.